Skip to main content

Theme news

Explore fairsonline.org coverage by editorial theme. Select a theme to see focused stories on innovation, strategy and market change.

Global Sports and Leisure Infrastructure Gears Up for FSB 2025 in Cologne

Submitted by J. Mikhail on
Image
Global Sports and Leisure Infrastructure Gears Up for FSB 2025 in Cologne

SHERIDAN, WYOMING – October 21, 2025 – The global sports, leisure, and public space industries are preparing for a major milestone event as FSB 2025, the International Trade Fair for Public Space, Sports, and Leisure Facilities, opens its doors in Cologne from October 28 to 31, 2025. Poised to be the world’s largest gathering in its sector, this year’s edition underscores the industry’s rebound and innovation drive, highlighting sustainable urban planning, digital infrastructure, and inclusive design across more than 70,000 square meters of exhibition space.

A Record-Breaking Year for Exhibitor Participation

Diebold Nixdorf Reshapes Leadership to Accelerate Global Growth and Operational Excellence

Submitted by J. Mikhail on
Image
Diebold Nixdorf Reshapes Leadership to Accelerate Global Growth and Operational Excellence

SHERIDAN, WYOMING – October 15, 2025 – Diebold Nixdorf (NYSE: DBD), a global technology leader in connected commerce for banking and retail, has announced two key executive appointments aimed at unifying commercial operations and strengthening administrative efficiency worldwide. Joe Myers will become Chief Revenue Officer (CRO) starting January 1, 2026, while Elizabeth (Lisa) Radigan will assume the newly created role of Chief Administrative Officer (CAO) effective December 1, 2025.

Both appointments reflect Diebold Nixdorf’s continued focus on integrated growth strategies, cross-segment collaboration, and scalable operational models designed to support banks and retailers adapting to rapid digital transformation.

Unifying Sales to Drive Customer-Centric Growth

SIPA XTRA 8 Redefines Refillable PET Bottles with Smart, Sustainable Blowmolding Technology

Submitted by J. Mikhail on
Image
SIPA XTRA 8 Redefines Refillable PET Bottles with Smart, Sustainable Blowmolding Technology

SHERIDAN, WYOMING – October 15, 2025 – SIPA is charting the future of refillable PET packaging with the debut of its XTRA 8 rotary blowmolder at Drinktec 2025, introducing an advanced, digitally intelligent platform that blends speed, sustainability, and precision engineering. Designed for the next generation of returnable bottle systems, the XTRA 8 positions SIPA as a frontrunner in the race toward smarter and greener beverage production.

SIPA’s XLABL RF Sets a New Standard for High-Speed Roll-Fed Labelling in PET Bottling

Submitted by J. Mikhail on
Image
SIPA’s XLABL RF Sets a New Standard for High-Speed Roll-Fed Labelling in PET Bottling

SHERIDAN, WYOMING – October 15, 2025 – SIPA, a global leader in PET packaging and bottling technology, has introduced its new XLABL RF rotary roll-fed labeller — a breakthrough that completes the company’s fully integrated Sincro Tribloc System. This new machine enables a unified production flow from blowing and filling to labelling, achieving record-setting speeds of up to 90,000 bottles per hour.

A Fully Integrated Bottling Workflow for Modern Production Lines
The addition of the XLABL RF transforms SIPA’s Sincro Tribloc into a fully synchronized, closed-loop solution that minimizes complexity, reduces downtime, and elevates output efficiency. By integrating the labelling phase directly into the production sequence, manufacturers can streamline their operations without sacrificing precision or consistency.

SIPA’s XFORM PRO and XBrain: Redefining High-Cavitation PET Preform Production with Intelligent Efficiency

Submitted by J. Mikhail on
Image
SIPA’s XFORM PRO and XBrain: Redefining High-Cavitation PET Preform Production with Intelligent Efficiency

SHERIDAN, WYOMING – October 15, 2025 – SIPA has unveiled the XFORM PRO, a next-generation PET preform system that merges mechanical innovation with digital intelligence. Building on the success of the XFORM Gen 4, the new platform delivers faster cycles, lower energy use, and seamless integration with the company’s new XBrain telemetric mold management system—marking a major leap forward in high-cavitation PET preform manufacturing.

SIPA Expands Preform Manufacturing Range with Compact and Scalable XFORM 160 System

Submitted by J. Mikhail on
Image
SIPA Expands Preform Manufacturing Range with Compact and Scalable XFORM 160 System

SHERIDAN, WYOMING – October 15, 2025 – Italian packaging technology leader SIPA has introduced the new XFORM 160, a smart and scalable preform production system that targets low- to mid-volume bottlers and converters seeking high performance without high complexity. Positioned as the entry-level model in SIPA’s now fully integrated XFORM lineup—which includes the 160, 250, 350, and 500 systems—the machine marks a strategic move to make advanced preform manufacturing accessible to a broader range of producers.

Smart, Sustainable, and Scalable Performance
The XFORM 160 is designed to meet the shifting needs of a dynamic packaging market where sustainability, agility, and modular growth are key. With a compact footprint and plug-and-play setup, the system enables rapid installation and adaptability for small-scale bottlers, specialty converters, and new entrants to the PET packaging segment.

SIPA’s Sincro Tribloc Redefines PET Bottling with Fully Integrated High-Speed Line

Submitted by J. Mikhail on
Image
SIPA’s Sincro Tribloc Redefines PET Bottling with Fully Integrated High-Speed Line

SHERIDAN, WYOMING – October 15, 2025 – SIPA has introduced the Sincro Tribloc, a fully integrated PET bottling solution that combines blowing, labelling, and filling in one compact unit. Designed for ultra-high-speed operations of up to 90,000 bottles per hour, the system redefines efficiency and sustainability standards for beverage manufacturers seeking leaner production and reduced total cost of ownership.

SIPA Launches ECS SP130 to Redefine ISBM Packaging Efficiency and Flexibility

Submitted by J. Mikhail on
Image
SIPA Launches ECS SP130 to Redefine ISBM Packaging Efficiency and Flexibility

SHERIDAN, WYOMING – October 15, 2025 – Italian engineering firm SIPA has unveiled the ECS SP130, a next-generation Injection-Stretch-Blow Molding (ISBM) system that marks a major leap forward in packaging production. Designed entirely in Italy, the new machine is built to set a new global benchmark for productivity, quality, and operational versatility in the manufacturing of plastic containers.

Reinventing Performance and Clean Production Standards
The ECS SP130 is engineered to meet the most demanding industrial environments. Capable of handling blow pressures up to 38 bar, it ensures consistent performance even for containers with complex geometries. A “Clean Tech” system eliminates any risk of oil contamination in bottles — a crucial advantage for food and beverage applications where hygiene and purity are non-negotiable.

Lilly’s Oral GLP-1 Candidate Outperforms AstraZeneca’s Farxiga in Late-Stage Diabetes Trials

Submitted by J. Mikhail on
Image
Lilly’s Oral GLP-1 Candidate Outperforms AstraZeneca’s Farxiga in Late-Stage Diabetes Trials

SHERIDAN, WYOMING – October 15, 2025 – Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron, has achieved another major milestone in its late-stage clinical program. Following its earlier success against Novo Nordisk’s semaglutide, the once-daily oral therapy has now demonstrated superiority over AstraZeneca’s blockbuster Farxiga (dapagliflozin) in two Phase III studies targeting patients with inadequately controlled type 2 diabetes.

Strong Phase III Results Reinforce Competitive Edge
The twin trials, ACHIEVE-2 and ACHIEVE-5, assessed orforglipron’s efficacy and safety in patients whose diabetes remained poorly controlled despite metformin therapy. Both studies met their primary and secondary endpoints, showing significant improvements in key glycemic markers and body weight after 40 weeks of treatment.

Sarepta’s SRP-9003 Gene Therapy Shows Clinical Promise but Faces FDA Uncertainty

Submitted by J. Mikhail on
Image
Sarepta’s SRP-9003 Gene Therapy Shows Clinical Promise but Faces FDA Uncertainty

SHERIDAN, WYOMING – October 15, 2025 – Sarepta Therapeutics is pressing forward with its limb-girdle muscular dystrophy (LGMD) gene therapy, SRP-9003, despite a strategic pivot earlier this year toward small interfering RNA (siRNA) therapies and ongoing regulatory challenges. New late-stage data presented at the World Muscle Society Congress in Vienna suggest the therapy could still hold clinical and commercial potential—if Sarepta can navigate FDA scrutiny and rebuild trust in its gene therapy platform.

Promising Clinical Outcomes at WMS 2025
At the 30th annual World Muscle Society (WMS) meeting, Sarepta shared Phase III data from its EMERGENE trial evaluating SRP-9003 in 17 LGMD patients. The therapy, designed to restore beta-sarcoglycan expression—a key muscle-stabilizing protein—met its primary endpoint after 60 days of observation.

Pelage Pharmaceuticals Secures $120 Million to Advance Stem Cell-Based Hair Regrowth Therapy into Phase III

Submitted by J. Mikhail on
Image
Pelage Pharmaceuticals Secures $120 Million to Advance Stem Cell-Based Hair Regrowth Therapy into Phase III

SHERIDAN, WYOMING – October 15, 2025 – Pelage Pharmaceuticals has raised $120 million in Series B financing to advance its novel stem cell–activating therapy for hair loss into Phase III clinical trials. The funding positions the California-based biotech to accelerate clinical development of PP405, a first-in-class topical molecule designed to rejuvenate dormant hair follicle stem cells and restore natural hair growth.

Boehringer Ingelheim Expands Oncology Portfolio With $991 Million AimedBio Antibody-Drug Conjugate Deal

Submitted by J. Mikhail on
Image
Boehringer Ingelheim Expands Oncology Portfolio With $991 Million AimedBio Antibody-Drug Conjugate Deal

SHERIDAN, WYOMING – October 15, 2025 – Boehringer Ingelheim is continuing its high-stakes investment strategy in next-generation oncology treatments, signing a deal worth up to $991 million with South Korea’s AimedBio to license an antibody-drug conjugate (ADC) for cancer. The move underscores Boehringer’s accelerating focus on precision oncology and reinforces its growing footprint in the ADC space—one of the most competitive frontiers in cancer therapeutics.

Bristol Myers Squibb Extends $2B+ AI Drug Discovery Pact with Insitro to Advance ALS Research

Submitted by J. Mikhail on
Image
Bristol Myers Squibb Extends $2B+ AI Drug Discovery Pact with Insitro to Advance ALS Research

SHERIDAN, WYOMING – October 15, 2025 – Bristol Myers Squibb (BMS) has expanded its artificial intelligence-driven collaboration with insitro, reinforcing its long-term strategy to accelerate therapeutic development in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The renewed deal underscores a shared commitment to leveraging AI and advanced chemistry platforms to unlock new pathways in ALS drug discovery.

AI-Powered Extension Strengthens a Five-Year Alliance

The latest extension adds another year to the 2020 collaboration, with BMS investing up to $20 million to continue joint research using insitro’s advanced ChemML platform. The total deal value could exceed $2 billion through potential discovery, development, and commercial milestones, as well as royalties on any approved therapies.

BioCryst Expands Hereditary Angioedema Portfolio with $700M Astria Therapeutics Acquisition

Submitted by J. Mikhail on
Image
BioCryst Expands Hereditary Angioedema Portfolio with $700M Astria Therapeutics Acquisition

SHERIDAN, WYOMING – October 15, 2025 – BioCryst Pharmaceuticals is strengthening its hereditary angioedema (HAE) pipeline through the acquisition of Massachusetts-based Astria Therapeutics in a $700 million cash-and-stock deal. The move positions BioCryst to compete more aggressively in the rare disease market by combining its oral HAE treatment, Orladeyo, with Astria’s long-acting injectable candidate, navenibart.

Strategic Expansion into Injectable HAE Therapy
The acquisition gives BioCryst a promising investigational monoclonal antibody, navenibart, currently in Phase III trials for HAE prophylaxis. Designed to inhibit plasma kallikrein — a key driver of HAE attacks — the therapy could offer significant convenience and efficacy improvements over existing injectable options.

FDA Grants Krystal Biotech Platform Technology Designation, Marking Strategic Shift in Gene Therapy Oversight

Submitted by J. Mikhail on
Image
FDA Grants Krystal Biotech Platform Technology Designation, Marking Strategic Shift in Gene Therapy Oversight

SHERIDAN, WYOMING – October 15, 2025 – In a pivotal development for the U.S. biotech sector, Krystal Biotech has received the U.S. Food and Drug Administration’s (FDA) second-ever platform technology designation for its non-replicating HSV-1 viral vector—positioning the company as a key early beneficiary of the agency’s emerging regulatory framework for gene therapy platforms.

Validation of a Versatile Gene Delivery Platform

The FDA’s platform designation recognizes Krystal’s HSV-1 vector technology as a “well-understood and reproducible” delivery system capable of supporting multiple gene therapy programs. Analysts at William Blair described Krystal as “poised to be the first major beneficiary” of this program, highlighting the FDA’s confidence in the HSV-1 vector’s cross-program applicability.

Heidelberg and MK Masterwork Extend Strategic Partnership to Drive Automation in Global Packaging Production

Submitted by J. Mikhail on
Image
Heidelberg and MK Masterwork Extend Strategic Partnership to Drive Automation in Global Packaging Production

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) and China’s MK Masterwork are deepening their decade-long collaboration to advance automation and robotics in packaging production. The renewed strategic partnership, announced at a joint anniversary event in Tianjin, underscores both companies’ commitment to delivering integrated, end-to-end solutions for the global packaging and printing industry.

A Decade of Partnership Strengthening Global Reach

Since entering a strategic sales agreement in 2015, HEIDELBERG has distributed MK Masterwork’s high-performance finishing systems—including die-cutters, folding carton gluers, and hot-foil stamping machines—outside of China. Over the past decade, approximately 1,500 systems have been installed worldwide, supporting packaging manufacturers in achieving higher efficiency and throughput.

HEIDELBERG’s SHIFT 2025 Showcases AI-Driven Printing Workflows and Hybrid Production Future

Submitted by J. Mikhail on
Image
HEIDELBERG’s SHIFT 2025 Showcases AI-Driven Printing Workflows and Hybrid Production Future

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) brought together more than 200 global industry leaders at its new SHIFT 2025 summit to address one of the printing sector’s most pressing challenges: how to remain competitive amid rising costs, labor shortages, and increasingly fragmented order structures. The event underscored the company’s commitment to driving end-to-end process digitization, automation, and hybrid print production through its evolving Prinect workflow platform and AI-supported solutions like Prinect Touch Free.

Gallus and HEIDELBERG Redefine Digital Label Production with Hybrid and Entry-Level Presses at Labelexpo Europe 2025

Submitted by J. Mikhail on
Image
Gallus and HEIDELBERG Redefine Digital Label Production with Hybrid and Entry-Level Presses at Labelexpo Europe 2025

SHERIDAN, WYOMING – October 15, 2025 – At Labelexpo Europe 2025 in Barcelona, Gallus and Heidelberger Druckmaschinen AG (HEIDELBERG) unveiled a next-generation suite of digital and hybrid label printing technologies designed to accelerate digital adoption across the global label industry. With the introduction of the Gallus Five and Gallus Alpha presses—alongside a new Gallus Print Academy—the companies are positioning themselves at the forefront of connected, high-performance printing for converters seeking flexibility, cost efficiency, and industrial productivity.

Hybrid and Digital Innovation to Drive Industry Transition

HEIDELBERG and Solenis Unveil Inline Barrier Coating Breakthrough for Sustainable Flexible Paper Packaging

Submitted by J. Mikhail on
Image
HEIDELBERG and Solenis Unveil Inline Barrier Coating Breakthrough for Sustainable Flexible Paper Packaging

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) and Solenis are redefining the future of sustainable packaging with a newly developed inline process that applies functional barrier coatings directly within the flexographic printing workflow. The innovation, integrated into HEIDELBERG’s high-volume Boardmaster system, aims to make paper-based flexible packaging a viable and economical alternative to plastic — accelerating the “paperization” trend across the global packaging industry.

Driving Sustainability Through Technological Integration

EGGER Introduces DecoWall: A Sustainable, Design-Driven Solution for Modern Interior Professionals

Submitted by J. Mikhail on
Image
EGGER Introduces DecoWall: A Sustainable, Design-Driven Solution for Modern Interior Professionals

SHERIDAN, WYOMING – October 15, 2025 – EGGER, a leading European manufacturer of wood-based materials, has launched DecoWall, an innovative wall panel system that combines sustainable engineering with design flexibility for residential and commercial interiors. Designed to meet the growing demand for eco-conscious and easy-to-install wall solutions, DecoWall merges technical performance with aesthetic appeal — making it ideal for professional installers, architects, and designers seeking both function and form.